Biodesix (BDSX) Change in Accured Expenses (2019 - 2026)

Biodesix (BDSX) has 8 years of Change in Accured Expenses data on file, last reported at -$2.3 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 20.95% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 55.73% YoY) and the FY2025 annual result came in at $1.9 million, up 13.56% from the prior year.
• Change in Accured Expenses declined to -$2.3 million in Q1 2026, from $974000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q2 2023 to a low of -$2.3 million in Q1 2026.
• A 5-year average of $52470.6 and a median of $486000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2897.25% in 2023, down 370.13% in 2023.
• Tracing BDSX's Change in Accured Expenses over 5 years: stood at -$127000.0 in 2022, then jumped by 698.43% to $760000.0 in 2023, then jumped by 122.89% to $1.7 million in 2024, then sank by 42.5% to $974000.0 in 2025, then plunged by 340.66% to -$2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.3 million (Q1 2026), $974000.0 (Q4 2025), and $486000.0 (Q3 2025), per Business Quant data.